ERIC BENEVICH Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for ERIC BENEVICH.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of ERIC BENEVICH. ERIC BENEVICH is Chief Commercial Officer in NEUROCRINE BIOSCIENCES INC ($NBIX).
Latest Insider Trading Transactions of ERIC BENEVICH
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 0.00 | 7,439 | 0 | 7,439 | |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 117.63 | 44,632 | 5,250,062 | 44,632 | |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 116.84 | 2,030 | 237,186 | 21,099 | 23.1 K to 21.1 K (-8.78 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 116.76 | 1,395 | 162,880 | 19,273 | 20.7 K to 19.3 K (-6.75 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 116.89 | 845 | 98,775 | 18,018 | 18.9 K to 18 K (-4.48 %) |
| Feb 09 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 114.03 | 809 | 92,247 | 16,434 | 17.2 K to 16.4 K (-4.69 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | M | 41.78 | 300 | 12,534 | 56,223 | |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | M | 41.78 | 3,477 | 145,269 | 56,523 | |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 120.00 | 100 | 12,000 | 15,705 | 15.8 K to 15.7 K (-0.63 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 120.00 | 300 | 36,000 | 15,805 | 16.1 K to 15.8 K (-1.86 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Buy | M | 41.78 | 300 | 12,534 | 16,105 | 15.8 K to 16.1 K (+1.90 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 120.03 | 1,600 | 192,044 | 15,805 | 17.4 K to 15.8 K (-9.19 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 120.03 | 3,477 | 417,327 | 17,405 | 20.9 K to 17.4 K (-16.65 %) |
| Jan 27 2021 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Buy | M | 41.78 | 3,477 | 145,269 | 20,882 | 17.4 K to 20.9 K (+19.98 %) |
| Nov 16 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 90.71 | 2,257 | 204,723 | 17,405 | 19.7 K to 17.4 K (-11.48 %) |
| Nov 04 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | M | 35.99 | 20,595 | 741,214 | 7,775 | |
| Nov 04 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 96.53 | 20,595 | 1,987,972 | 15,374 | 36 K to 15.4 K (-57.26 %) |
| Nov 04 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Buy | M | 35.99 | 20,595 | 741,214 | 35,969 | 15.4 K to 36 K (+133.96 %) |
| Aug 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 118.85 | 2,257 | 268,254 | 15,374 | 17.6 K to 15.4 K (-12.80 %) |
| Apr 28 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 99.45 | 1,934 | 192,338 | 13,344 | 15.3 K to 13.3 K (-12.66 %) |
| Apr 17 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 94.65 | 8,632 | 817,018 | 11,603 | 20.2 K to 11.6 K (-42.66 %) |
| Feb 11 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 103.32 | 2,030 | 209,747 | 20,087 | 22.1 K to 20.1 K (-9.18 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 0.00 | 9,719 | 0 | 9,719 | |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 102.90 | 61,347 | 6,312,606 | 61,347 | |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 101.48 | 1,395 | 141,561 | 18,262 | 19.7 K to 18.3 K (-7.10 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 102.90 | 809 | 83,248 | 17,007 | 17.8 K to 17 K (-4.54 %) |
| Feb 07 2020 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 103.11 | 1,145 | 118,063 | 16,279 | 17.4 K to 16.3 K (-6.57 %) |
| Jul 17 2019 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 87.44 | 5,835 | 510,201 | 14,910 | 20.7 K to 14.9 K (-28.13 %) |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 0.00 | 15,423 | 0 | 15,423 | |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 81.05 | 83,341 | 6,754,788 | 83,341 | |
| Feb 08 2019 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 83.57 | 920 | 76,883 | 20,745 | 21.7 K to 20.7 K (-4.25 %) |
| Feb 06 2019 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 87.95 | 755 | 66,401 | 19,015 | 19.8 K to 19 K (-3.82 %) |
| Feb 06 2019 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 88.08 | 602 | 53,026 | 17,595 | 18.2 K to 17.6 K (-3.31 %) |
| Jun 05 2018 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 97.34 | 12,350 | 1,202,164 | 16,690 | 29 K to 16.7 K (-42.53 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 0.00 | 12,250 | 0 | 12,250 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 0.00 | 6,150 | 0 | 6,150 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 81.49 | 34,750 | 2,831,778 | 34,750 | |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Payment of Exercise | F | 82.48 | 917 | 75,634 | 4,310 | 5.2 K to 4.3 K (-17.54 %) |
| Feb 07 2018 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 83.14 | 820 | 68,174 | 2,577 | 3.4 K to 2.6 K (-24.14 %) |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 0.00 | 10,600 | 0 | 10,600 | |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 43.24 | 76,800 | 3,320,832 | 76,800 | |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 44.65 | 132 | 5,894 | 1,222 | 1.4 K to 1.2 K (-9.75 %) |
| Feb 08 2017 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Sell | S | 43.11 | 821 | 35,393 | 0 | 821 to 0 (-100.00 %) |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 0.00 | 20,500 | 0 | 20,500 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 35.99 | 41,200 | 1,482,788 | 41,200 | |
| Feb 09 2016 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 0.00 | 8,700 | 0 | 8,700 | |
| Jun 03 2015 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 | |
| Jun 03 2015 | NBIX | NEUROCRINE BIOSCIE ... | BENEVICH ERIC | Chief Commercial Of ... | Option Exercise | A | 41.78 | 60,000 | 2,506,800 | 60,000 |
Page: 1